Present-day conservative treatment retinopathy of prematurity

Area of Science:

• Ophthalmology
• Neonatology
• Developmental Biology

Background:

• Retinopathy of prematurity (ROP) is a significant cause of vision loss and blindness in premature infants worldwide.
• The multifactorial etiology and increasing diagnosis rates of ROP necessitate novel therapeutic strategies.
• Current treatments like laser, cryotherapy, and surgery have limitations, driving the search for more effective interventions.

Purpose of the Study:

• To conduct a detailed literature review on emerging management strategies for retinopathy of prematurity.
• To explore the role of vascular endothelial growth factor (VEGF) in ROP pathogenesis and therapeutic targeting.
• To assess the potential of novel agents and gene therapy in treating ROP.

Main Methods:

• Literature review of recent studies on ROP management.
• Analysis of research on VEGF inhibitors (ranibizumab, bevacizumab) in ROP treatment.
• Examination of experimental therapies including Triamcinolone, gene therapy, and other novel agents.

Main Results:

• Vitreous application of VEGF inhibitors is explored as an adjunct or alternative to conventional therapies, though controversies exist.
• Experimental treatments like Triamcinolone and agents inhibiting fibro-vascular proliferation are under investigation.
• Emerging therapies include gene therapy, beta-blockers, Omega-3 fatty acids, MMP-2 inhibitors, gold nanoparticles, and anthrax lethal toxin.

Conclusions:

• Novel therapeutic approaches, particularly targeting VEGF, offer potential advancements in ROP management.
• Further research is needed to establish the efficacy and safety of these emerging treatments.
• A combination of therapies may be required for optimal outcomes in complex ROP cases.